Kinetics of SARS-CoV-2-specific antibodies among inactivated COVID-19 vaccine recipients, SARS-CoV-2 natural infection cases, and breakthrough cases.
10.3760/cma.j.cn112150-20220621-00639
- Author:
Lai Run JIN
1
;
Chu Chu LI
2
;
Cong CHEN
3
;
Yin WANG
4
;
Yan WANG
5
;
Min HE
6
;
Song Ning DING
7
;
Ming Wei WEI
2
;
Hua TIAN
2
;
Xiao Xiao KONG
2
;
Chen DONG
2
;
Lu ZHOU
2
;
Jie Fu PENG
2
;
Zhi Guo WANG
2
;
Feng Cai ZHU
2
;
Li Guo ZHU
8
Author Information
1. School of Public Health, Southeast University, Nanjing 210009, China.
2. Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
3. Institute of Acute Infectious Disease Control, Changzhou Municipal Center for Disease Control and Prevention, Changzhou 213000, China.
4. Institute of Acute Infectious Disease Control, Yangzhou Municipal Center for Disease Control and Prevention, Yangzhou 225000, China.
5. Laboratory Department, Yangzhou Municipal Center for Disease Control and Prevention, Yangzhou 225000, China.
6. Laboratory Department, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China.
7. Institute of Acute Infectious Disease Control, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China.
8. School of Public Health, Southeast University, Nanjing 210009, China Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Aged;
Middle Aged;
Young Adult;
Adult;
Aged, 80 and over;
Adolescent;
COVID-19 Vaccines;
COVID-19;
SARS-CoV-2;
Kinetics;
Antibodies, Viral;
Immunoglobulin G
- From:
Chinese Journal of Preventive Medicine
2022;56(12):1834-1837
- CountryChina
- Language:Chinese
-
Abstract:
Between August and September, 2021, this study included 605 SARS-CoV-2 natural infection cases and 589 SARS-CoV-2 breakthrough cases from Nanjing and Yangzhou, as well as 690 inactivated COVID-19 vaccine recipients from Changzhou, China. In SARS-CoV-2 natural infection cases, the age range was 19-91 years (median age: 66 year), and the medians(Q1,Q3) of IgG titers were 0.19 (0.06-1.31), 3.70 (0.76-69.48), 15.31 (2.59-82.16), 4.41 (0.99-31.74), 2.31 (0.75-13.83), 2.28 (0.68-9.94) and 2.80 (1.00-9.53) at one to seven weeks after SARS-CoV-2 infection, respectively. In SARS-CoV-2 breakthrough cases, the age range was 18-76 years (median age: 45 year), and the medians(Q1,Q3)of IgG titers were 1.93 (0.34-26.67), 38.87 (7.90-121.0), 75.09 (11.85-123.70), 21.97 (5.20-95.58), 13.97 (3.47-46.82), 9.56 (2.48-33.38) and 4.38 (1.87-11.00) at one to seven weeks after SARS-CoV-2 infection, respectively. In inactivated COVID-19 vaccine recipients, the age range was 18-87 years (median age: 47 years), and the medians(Q1,Q3)of IgG titers were 16.22 (15.84-33.42), 5.35 (2.96-13.23), 3.30 (2.18-6.18), 3.14 (1.16-5.70), 2.77 (1.50-4.52), 2.72 (1.76-4.36), 2.01 (1.27-3.51) and 1.94 (1.35-3.09) at one to eight months after SARS-CoV-2 infection, respectively. The results suggested that IgG antibodies increased gradually within two weeks after SARS-CoV-2 infection, then declined gradually at three to seven weeks in SARS-CoV-2 natural infection cases. In SARS-CoV-2 breakthrough cases, IgG antibodies increased rapidly within two weeks, then declined gradually at three to seven weeks after SARS-CoV-2 infection. Additionally, IgG antibodies decreased rapidly within three months, then decreased gradually and remained at a low level within three months after immunization.
